Prostate Cancer Screening Found Very Effective
Prostate-specific antigen (PSA) screening was associated with better oncologic outcomes in African American patients with prostate cancer, according to data presented by Edmund M. Qiao, BS, of the University of California San Diego, reported Audrey Sternberg with The Cancer Network on May 20, 2021.
An increase in the frequency of PSA screening was linked to a nearly 25% reduction in prostate cancer-specific mortality and an approximately 40% lower risk of having the metastatic disease at the time of a prostate cancer diagnosis.
The “high PSA screening” group had received an average of 3 prior screening tests, and the “low PSA screening” group had received an average of 0.5 prior screening tests.
Overall, the study included 4,726 African American men diagnosed with prostate cancer. The mean patient age was 51.8 years. The mean number of previous PSA screening tests was 1.9.
The US Preventive Services Task Force PSA screening policy is a grade C recommendation for men aged 55 to 69 years, meaning in this population, an individual decision on screening should be made based on a physician-clinician discussion of the potential benefits and risks.